

# **Global Myocardial Infarction Therapeutics Market Size Study, by Therapeutic Class (Antiplatelet Agents, Antithrombotic Agents, Nitrates, Calcium Channel Blockers, Lipid-Lowering Agents), by Route of Administration (Oral, Intravenous, Subcutaneous, Transdermal), by Indication (ST-Elevation Myocardial Infarction (STEMI), Non-ST-Elevation Myocardial Infarction (NSTEMI), Unstable Angina), by Mechanism of Action (Platelet Aggregation Inhibitors, Thrombin Inhibitors, Anticoagulants, Calcium Channel Blockers, HMG-CoA Reductase Inhibitors) and Regional Forecasts 2024-2032**

<https://marketpublishers.com/r/G1532CF8E9E6EN.html>

Date: October 2024

Pages: 285

Price: US\$ 3,218.00 (Single User License)

ID: G1532CF8E9E6EN

## **Abstracts**

The Global Myocardial Infarction Therapeutics Market is estimated to be valued at USD 15.56 billion in 2023 and is projected to grow at a CAGR of 4.19% over the forecast period 2024-2032. Myocardial infarction therapeutics encompass a range of treatments aimed at managing and mitigating the effects of a heart attack. These include acute interventions such as thrombolytic therapy, which dissolves blood clots obstructing coronary arteries, and percutaneous coronary interventions (PCI), such as angioplasty and stent placement to restore blood flow. Medications play a crucial role, including antiplatelet agents, anticoagulants, and beta-blockers, which reduce the heart's workload and prevent further clot formation. Long-term management may involve lifestyle modifications, statins to manage cholesterol levels, and medications to control blood pressure. Collectively, these strategies aim to restore heart function, prevent

complications, and improve overall prognosis. Furthermore, advances in pharmacology are leading to the development of novel drugs, including new anticoagulants, antiplatelet agents, and drugs targeting specific pathways involved in myocardial infarction. These innovations aim to improve efficacy and reduce side effects.

The substantial growth can be attributed to the increasing prevalence of cardiovascular diseases (CVDs), which have been the leading cause of death globally for the past 15 years. Factors such as sedentary lifestyles, unhealthy diets, tobacco use, and an aging population further contribute to the rising incidence of myocardial infarction, driving the demand for effective therapeutic solutions. Technological advancements in treatment modalities are another significant driver of market growth. Continuous innovation in drug development, including the introduction of novel therapies such as gene therapy, stem cell therapy, and personalized medicine approaches, is expected to enhance treatment outcomes and reduce mortality rates. The adoption of telemedicine and remote patient monitoring also facilitates better access to healthcare services, especially in underserved regions, thus expanding the market reach.

The key region in the Global Myocardial Infarction Therapeutics Market includes North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. In 2023, North America dominates the market in terms of revenue, supported by a well-established healthcare infrastructure, high prevalence of cardiovascular diseases, and robust research and development activities. The region benefits from cutting-edge treatments, including innovative drugs and advanced medical technologies, alongside a strong emphasis on healthcare access and patient management, driving its leading market position. Europe follows closely, driven by an increasing geriatric population and rising healthcare expenditure. The Asia-Pacific region is expected to grow at the fastest growth rate during the forecast period 2024-2032, due to heightened awareness about cardiovascular health, improving healthcare systems, and rising disposable incomes.

Major market players included in this report are:

Bayer AG

Eli Lilly and Company

Johnson & Johnson

Bristol-Myers Squibb Company

Boehringer Ingelheim International GmbH

Merck & Co., Inc.

Teva Pharmaceutical Industries Ltd.

Abbott Laboratories

Novartis AG

Sanofi Aventis US, LLC

AstraZeneca plc

Pfizer Inc.

Roche Holding AG

The detailed segments and sub-segment of the market are explained below:

By Therapeutic Class:

Antiplatelet Agents

Antithrombotic Agents

Nitrates

Calcium Channel Blockers

Lipid-Lowering Agents

By Route of Administration:

Oral

Intravenous

Subcutaneous

Transdermal

By Indication:

ST-Elevation Myocardial Infarction (STEMI)

Non-ST-Elevation Myocardial Infarction (NSTEMI)

Unstable Angina

By Mechanism of Action:

Platelet Aggregation Inhibitors (P2Y<sub>12</sub> Inhibitors, GPIIb/IIIa Inhibitors)

Thrombin Inhibitors

Anticoagulants

Calcium Channel Blockers

HMG-CoA Reductase Inhibitors

By Region:

North America

U.S.

Canada

Europe

UK

Germany

France

Spain

Italy

ROE

Asia Pacific

China

India

Japan

Australia

South Korea

RoAPAC

Latin America

Brazil

Mexico

Rest of Latin America

Middle East & Africa

Saudi Arabia

South Africa

RoMEA

Years considered for the study are as follows:

Historical year – 2022

Base year – 2023

Forecast period – 2024 to 2032

Key Takeaways:

Market Estimates & Forecast for 10 years from 2022 to 2032.

Annualized revenues and regional level analysis for each market segment.

Detailed analysis of geographical landscape with country level analysis of major regions.

Competitive landscape with information on major players in the market.

Analysis of key business strategies and recommendations on future market approach.

Analysis of competitive structure of the market.

Demand side and supply side analysis of the market.

## Contents

### **CHAPTER 1. GLOBAL MYOCARDIAL INFARCTION THERAPEUTICS MARKET EXECUTIVE SUMMARY**

- 1.1. Global Myocardial Infarction Therapeutics Market Size & Forecast (2022-2032)
- 1.2. Regional Summary
- 1.3. Segmental Summary
  - 1.3.1. By Therapeutic Class
  - 1.3.2. By Route of Administration
  - 1.3.3. By Indication
  - 1.3.4. By Mechanism of Action
- 1.4. Key Trends
- 1.5. Recession Impact
- 1.6. Analyst Recommendation & Conclusion

### **CHAPTER 2. GLOBAL MYOCARDIAL INFARCTION THERAPEUTICS MARKET DEFINITION AND RESEARCH ASSUMPTIONS**

- 2.1. Research Objective
- 2.2. Market Definition
- 2.3. Research Assumptions
  - 2.3.1. Inclusion & Exclusion
  - 2.3.2. Limitations
  - 2.3.3. Supply Side Analysis
    - 2.3.3.1. Availability
    - 2.3.3.2. Infrastructure
    - 2.3.3.3. Regulatory Environment
    - 2.3.3.4. Market Competition
    - 2.3.3.5. Economic Viability (Consumer's Perspective)
  - 2.3.4. Demand Side Analysis
    - 2.3.4.1. Regulatory Frameworks
    - 2.3.4.2. Technological Advancements
    - 2.3.4.3. Environmental Considerations
    - 2.3.4.4. Consumer Awareness & Acceptance
- 2.4. Estimation Methodology
- 2.5. Years Considered for the Study
- 2.6. Currency Conversion Rates

## **CHAPTER 3. GLOBAL MYOCARDIAL INFARCTION THERAPEUTICS MARKET DYNAMICS**

### **3.1. Market Drivers**

- 3.1.1. Rising Prevalence of Cardiovascular Diseases
- 3.1.2. Technological Advancements in MI Treatment
- 3.1.3. Increasing Healthcare Expenditure

### **3.2. Market Challenges**

- 3.2.1. High Cost of Treatment
- 3.2.2. Limited Accessibility in Developing Regions

### **3.3. Market Opportunities**

- 3.3.1. Development of Novel Treatments
- 3.3.2. Adoption of Telemedicine and Remote Patient Monitoring
- 3.3.3. Shift Towards Minimally Invasive Procedures

## **CHAPTER 4. GLOBAL MYOCARDIAL INFARCTION THERAPEUTICS MARKET INDUSTRY ANALYSIS**

### **4.1. Porter's 5 Force Model**

- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
- 4.1.6. Futuristic Approach to Porter's 5 Force Model
- 4.1.7. Porter's 5 Force Impact Analysis

### **4.2. PESTEL Analysis**

- 4.2.1. Political
- 4.2.2. Economical
- 4.2.3. Social
- 4.2.4. Technological
- 4.2.5. Environmental
- 4.2.6. Legal

### **4.3. Top Investment Opportunity**

### **4.4. Top Winning Strategies**

### **4.5. Disruptive Trends**

### **4.6. Industry Expert Perspective**

### **4.7. Analyst Recommendation & Conclusion**



## **CHAPTER 5. GLOBAL MYOCARDIAL INFARCTION THERAPEUTICS MARKET SIZE & FORECASTS BY THERAPEUTIC CLASS 2022-2032**

### 5.1. Segment Dashboard

### 5.2. Global Myocardial Infarction Therapeutics Market: Therapeutic Class Revenue Trend Analysis, 2022 & 2032 (USD Billion)

#### 5.2.1. Antiplatelet Agents

#### 5.2.2. Antithrombotic Agents

#### 5.2.3. Nitrates

#### 5.2.4. Calcium Channel Blockers

#### 5.2.5. Lipid-Lowering Agents

## **CHAPTER 6. GLOBAL MYOCARDIAL INFARCTION THERAPEUTICS MARKET SIZE & FORECASTS BY ROUTE OF ADMINISTRATION 2022-2032**

### 6.1. Segment Dashboard

### 6.2. Global Myocardial Infarction Therapeutics Market: Route of Administration Revenue Trend Analysis, 2022 & 2032 (USD Billion)

#### 6.2.1. Oral

#### 6.2.2. Intravenous

#### 6.2.3. Subcutaneous

#### 6.2.4. Transdermal

## **CHAPTER 7. GLOBAL MYOCARDIAL INFARCTION THERAPEUTICS MARKET SIZE & FORECASTS BY INDICATION 2022-2032**

### 7.1. Segment Dashboard

### 7.2. Global Myocardial Infarction Therapeutics Market: Indication Revenue Trend Analysis, 2022 & 2032 (USD Billion)

#### 7.2.1. ST-Elevation Myocardial Infarction (STEMI)

#### 7.2.2. Non-ST-Elevation Myocardial Infarction (NSTEMI)

#### 7.2.3. Unstable Angina

## **CHAPTER 8. GLOBAL MYOCARDIAL INFARCTION THERAPEUTICS MARKET SIZE & FORECASTS BY MECHANISM OF ACTION 2022-2032**

### 8.1. Segment Dashboard

### 8.2. Global Myocardial Infarction Therapeutics Market: Mechanism of Action Revenue Trend Analysis, 2022 & 2032 (USD Billion)

- 8.2.1. Platelet Aggregation Inhibitors (P2Y<sub>12</sub> Inhibitors, GPIIb/IIIa Inhibitors)
- 8.2.2. Thrombin Inhibitors
- 8.2.3. Anticoagulants
- 8.2.4. Calcium Channel Blockers
- 8.2.5. HMG-CoA Reductase Inhibitors

## **CHAPTER 9. GLOBAL MYOCARDIAL INFARCTION THERAPEUTICS MARKET SIZE & FORECASTS BY REGION 2022-2032**

- 9.1. North America Myocardial Infarction Therapeutics Market
  - 9.1.1. U.S. Myocardial Infarction Therapeutics Market
    - 9.1.1.1. Therapeutic Class Breakdown Size & Forecasts, 2022-2032
    - 9.1.1.2. Route of Administration Breakdown Size & Forecasts, 2022-2032
    - 9.1.1.3. Indication Breakdown Size & Forecasts, 2022-2032
    - 9.1.1.4. Mechanism of Action Breakdown Size & Forecasts, 2022-2032
  - 9.1.2. Canada Myocardial Infarction Therapeutics Market
- 9.2. Europe Myocardial Infarction Therapeutics Market
  - 9.2.1. U.K. Myocardial Infarction Therapeutics Market
  - 9.2.2. Germany Myocardial Infarction Therapeutics Market
  - 9.2.3. France Myocardial Infarction Therapeutics Market
  - 9.2.4. Spain Myocardial Infarction Therapeutics Market
  - 9.2.5. Italy Myocardial Infarction Therapeutics Market
  - 9.2.6. Rest of Europe Myocardial Infarction Therapeutics Market
- 9.3. Asia-Pacific Myocardial Infarction Therapeutics Market
  - 9.3.1. China Myocardial Infarction Therapeutics Market
  - 9.3.2. India Myocardial Infarction Therapeutics Market
  - 9.3.3. Japan Myocardial Infarction Therapeutics Market
  - 9.3.4. Australia Myocardial Infarction Therapeutics Market
  - 9.3.5. South Korea Myocardial Infarction Therapeutics Market
  - 9.3.6. Rest of Asia Pacific Myocardial Infarction Therapeutics Market
- 9.4. Latin America Myocardial Infarction Therapeutics Market
  - 9.4.1. Brazil Myocardial Infarction Therapeutics Market
  - 9.4.2. Mexico Myocardial Infarction Therapeutics Market
  - 9.4.3. Rest of Latin America Myocardial Infarction Therapeutics Market
- 9.5. Middle East & Africa Myocardial Infarction Therapeutics Market
  - 9.5.1. Saudi Arabia Myocardial Infarction Therapeutics Market
  - 9.5.2. South Africa Myocardial Infarction Therapeutics Market
  - 9.5.3. Rest of Middle East & Africa Myocardial Infarction Therapeutics Market

## **CHAPTER 10. COMPETITIVE INTELLIGENCE**

### 10.1. Key Company SWOT Analysis

10.1.1. Company

10.1.2. Company

10.1.3. Company

### 10.2. Top Market Strategies

### 10.3. Company Profiles

10.3.1. Bristol-Myers Squibb Company

10.3.1.1. Key Information

10.3.1.2. Overview

10.3.1.3. Financial (Subject to Data Availability)

10.3.1.4. Product Summary

10.3.1.5. Market Strategies

10.3.2. Boehringer Ingelheim International GmbH

10.3.3. Merck & Co., Inc.

10.3.4. Teva Pharmaceutical Industries Ltd.

10.3.5. Abbott Laboratories

10.3.6. Novartis AG

10.3.7. Sanofi Aventis US, LLC

10.3.8. AstraZeneca plc

10.3.9. Pfizer Inc.

10.3.10. Roche Holding AG

10.3.11. Bayer AG

10.3.12. Eli Lilly and Company

10.3.13. Johnson & Johnson

## **CHAPTER 11. RESEARCH PROCESS**

### 11.1. Research Process

11.1.1. Data Mining

11.1.2. Analysis

11.1.3. Market Estimation

11.1.4. Validation

11.1.5. Publishing

### 11.2. Research Attributes

## List Of Tables

### LIST OF TABLES

TABLE 1. Global Myocardial Infarction Therapeutics market, report scope

TABLE 2. Global Myocardial Infarction Therapeutics market estimates & forecasts by Region 2022-2032 (USD Billion)

TABLE 3. Global Myocardial Infarction Therapeutics market estimates & forecasts by Therapeutic Class 2022-2032 (USD Billion)

TABLE 4. Global Myocardial Infarction Therapeutics market estimates & forecasts by Route of Administration 2022-2032 (USD Billion)

TABLE 5. Global Myocardial Infarction Therapeutics market by segment, estimates & forecasts, 2022-2032 (USD Billion)

TABLE 6. Global Myocardial Infarction Therapeutics market by region, estimates & forecasts, 2022-2032 (USD Billion)

TABLE 7. Global Myocardial Infarction Therapeutics market by segment, estimates & forecasts, 2022-2032 (USD Billion)

TABLE 8. Global Myocardial Infarction Therapeutics market by region, estimates & forecasts, 2022-2032 (USD Billion)

TABLE 9. Global Myocardial Infarction Therapeutics market by segment, estimates & forecasts, 2022-2032 (USD Billion)

TABLE 10. Global Myocardial Infarction Therapeutics market by region, estimates & forecasts, 2022-2032 (USD Billion)

TABLE 11. Global Myocardial Infarction Therapeutics market by segment, estimates & forecasts, 2022-2032 (USD Billion)

TABLE 12. Global Myocardial Infarction Therapeutics market by region, estimates & forecasts, 2022-2032 (USD Billion)

TABLE 13. Global Myocardial Infarction Therapeutics market by segment, estimates & forecasts, 2022-2032 (USD Billion)

TABLE 14. Global Myocardial Infarction Therapeutics market by region, estimates & forecasts, 2022-2032 (USD Billion)

TABLE 15. U.S. Myocardial Infarction Therapeutics market estimates & forecasts, 2022-2032 (USD Billion)

TABLE 16. U.S. Myocardial Infarction Therapeutics market estimates & forecasts by segment 2022-2032 (USD Billion)

TABLE 17. U.S. Myocardial Infarction Therapeutics market estimates & forecasts by segment 2022-2032 (USD Billion)

TABLE 18. Canada Myocardial Infarction Therapeutics market estimates & forecasts, 2022-2032 (USD Billion)

TABLE 19. Canada Myocardial Infarction Therapeutics market estimates & forecasts by segment 2022-2032 (USD Billion)

TABLE 20. Canada Myocardial Infarction Therapeutics market estimates & forecasts by segment 2022-2032 (USD Billion)

.....

This list is not complete, the final report does contain more than 100 tables. The list may be updated in the final deliverable.

## List Of Figures

### LIST OF FIGURES

- FIG 1. Global Myocardial Infarction Therapeutics market, research methodology
- FIG 2. Global Myocardial Infarction Therapeutics market, market estimation techniques
- FIG 3. Global market size estimates & forecast methods.
- FIG 4. Global Myocardial Infarction Therapeutics market, key trends 2023
- FIG 5. Global Myocardial Infarction Therapeutics market, growth prospects 2022-2032
- FIG 6. Global Myocardial Infarction Therapeutics market, porters 5 force model
- FIG 7. Global Myocardial Infarction Therapeutics market, PESTEL analysis
- FIG 8. Global Myocardial Infarction Therapeutics market, value chain analysis
- FIG 9. Global Myocardial Infarction Therapeutics market by segment, 2022 & 2032 (USD Billion)
- FIG 10. Global Myocardial Infarction Therapeutics market by segment, 2022 & 2032 (USD Billion)
- FIG 11. Global Myocardial Infarction Therapeutics market by segment, 2022 & 2032 (USD Billion)
- FIG 12. Global Myocardial Infarction Therapeutics market by segment, 2022 & 2032 (USD Billion)
- FIG 13. Global Myocardial Infarction Therapeutics market by segment, 2022 & 2032 (USD Billion)
- FIG 14. Global Myocardial Infarction Therapeutics market, regional snapshot 2022 & 2032
- FIG 15. North America Myocardial Infarction Therapeutics market 2022 & 2032 (USD Billion)
- FIG 16. Europe Myocardial Infarction Therapeutics market 2022 & 2032 (USD Billion)
- FIG 17. Asia-Pacific Myocardial Infarction Therapeutics market 2022 & 2032 (USD Billion)
- FIG 18. Latin America Myocardial Infarction Therapeutics market 2022 & 2032 (USD Billion)
- FIG 19. Middle East & Africa Myocardial Infarction Therapeutics market 2022 & 2032 (USD Billion)
- FIG 20. Global Myocardial Infarction Therapeutics market, company market share analysis (2023)

.....

This list is not complete, the final report does contain more than 50 figures. The list may be updated in the final deliverable.

## I would like to order

Product name: Global Myocardial Infarction Therapeutics Market Size Study, by Therapeutic Class (Antiplatelet Agents, Antithrombotic Agents, Nitrates, Calcium Channel Blockers, Lipid-Lowering Agents), by Route of Administration (Oral, Intravenous, Subcutaneous, Transdermal), by Indication (ST-Elevation Myocardial Infarction (STEMI), Non-ST-Elevation Myocardial Infarction (NSTEMI), Unstable Angina), by Mechanism of Action (Platelet Aggregation Inhibitors, Thrombin Inhibitors, Anticoagulants, Calcium Channel Blockers, HMG-CoA Reductase Inhibitors) and Regional Forecasts 2024-2032

Product link: <https://marketpublishers.com/r/G1532CF8E9E6EN.html>

Price: US\$ 3,218.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G1532CF8E9E6EN.html>